Company Filing History:
1 out of 922 
1 out of 5,307 
1 out of 893 
Years Active: 2006-2025
Title: Innovations in Coagulation Therapy: The Patents of Lawrence L K Leung
Introduction
Lawrence L K Leung is an influential inventor based in Hillsborough, California, recognized for his innovative contributions to coagulation therapy. With a keen focus on biochemistry, he has developed novel solutions that enhance patient care in the field of anticoagulation.
Latest Patents
Lawrence holds a patent for "Polypeptides and coagulation therapy," which introduces novel polypeptides (NPs) capable of activating protein C without significant fibrinogen clotting activity. This innovative approach allows for the development of anticoagulants with enhanced protein C activating properties, while minimizing clotting issues. The NPs can be effectively used in screening substances that influence this property and in diagnostic procedures to assess the status of patients' protein C-mediated anticoagulant pathways. Furthermore, procoagulant NPs are beneficial for promoting clotting, particularly during therapy for solid tumors, serving as an impregnate for bandages, or in diagnostic assays. These NPs can be produced in recombinant cell culture or through in vitro methods.
Career Highlights
Lawrence is currently associated with Gilead Sciences, Inc., a leading biopharmaceutical company committed to advancing the care of patients with life-threatening diseases. His work has significantly impacted the development of therapeutic options in coagulation management, demonstrating his dedication to improving patient outcomes.
Collaborations
During his career, Lawrence has collaborated with notable colleagues, including Craig S Gibbs and Manuel Tsiang. These partnerships have contributed to the shared expertise and innovative spirit that drives progress in their field.
Conclusion
Lawrence L K Leung is a prominent figure in the field of coagulation therapy, with his invention of novel polypeptides making significant strides towards improved anticoagulant therapies. His dedication and collaboration with industry peers at Gilead Sciences, Inc. continue to foster advancements that enhance patient care and diagnostic procedures.